Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4- dihyropyridine)

Chemical Biology and Drug Design

Volumn 73, Issue 2, 2009, Pages 225-235

  Miri, Ramin ^a,b   Javidnia, Katayoun ^a,c   Hemmateenejad, Bahram ^a,d   Tabarzad, Maryam ^a,c   Jafarpour, Mehrnaz ^a,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY   (Iran)

Author keywords

1,4 dihydropyridines; Calcium channels antagonist activity; Quantitative structure activity relationship

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; 3,3' BUTANE 1,4 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' BUTANE 1,4 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' BUTANE 1,4 DIYL 5 DIMETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' ETHANE 1,2 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' ETHANE 1,2 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' ETHANE 1,2 DIYL 5 DIMETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEPTANE 1,6 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEPTANE 1,7 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEPTANE 1,7 DIYL 5 DIMETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEXANE 1,5 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEXANE 1,6 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEXANE 1,6 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEXANE 1,6 DIYL 5 DIMETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' HEXANE 1,7 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' PENTANE 1,5 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' PENTANE 1,5 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' PENTANE 1,5 DIYL 5 DIMETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' PROPANE 1,2 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' PROPANE 1,3 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' PROPANE 1,3 DIYL 5 DIETHYLBIS[2,6 DIMETHYL 4 (4 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; 3,3' PROPANE 1,3 DIYL 5 DIMETHYLBIS[2,6 DIMETHYL 4 (2 NITROPHENYL) 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE]; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL STIMULATING AGENT; NIFEDIPINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; IC 50; MALE; MICROWAVE RADIATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REACTION ANALYSIS; STEREOSPECIFICITY; STRUCTURE ANALYSIS;

ANIMALS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; GUINEA PIGS; INHIBITORY CONCENTRATION 50; MALE; MODELS, MOLECULAR; MUSCLE, SMOOTH; NIFEDIPINE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

CAVIA;

EID: 58849138873     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00770.x     Document Type: Article

References (30)

1. Triggle D.J. (1996) Ion channels as pharmacologic receptors: the chirality of drug interactions. Chirality 8 : 35 38.
2. Isom L.L., De Jongh K.S., Catterall W.A. (1994) Auxiliary subunits of voltage-gated ion channels. Neuron 12 : 1183 1194.
3. Fatt P., Katz B. (1953) The electrical properties of crustacean muscle fibres. J Physiol 120 : 171 204.
4. Fatt P., Ginsborg B.L. (1958) The ionic requirements for the production of action potentials in crustacean muscle fibres. J Physiol 142 : 516 543.
5. Hagiwara S., Byerly L. (1981) Calcium channel. Annu Rev Neurosci 4 : 69 125.
6. Cahalan M.D., Wulff H., Chandy K.G. (2001) Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 21 : 235 252.
7. Kim M.S., Morii T., Sun L.X., Imoto K., Mori Y. (1993) Structural determinants of ion selectivity in brain calcium channel. FEBS Lett 318 : 145 148.
8. 2+ channel antagonists. Trends Pharmacol Sci 13 : 256 262.
9. Fleckenstein A. (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 17 : 149 166.
10. Weiner D.A. (1988) Calcium channel blockers. Med Clin North Am 72 : 83 115.
11. Epstein M. (1997) The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk. Am J Cardiol 79 : 9 19 discussion 47-8.
12. Coburn R.A., Wierzba M., Suto M.J., Solo A.J., Triggle A.M., Triggle D.J. (1988) 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J Med Chem 31 : 2103 2107.
13. Dagnino L., Li-Kwong-Ken M.C., Wolowyk M.W., Wynn H., Triggle C.R., Knaus E.E. (1986) Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates. J Med Chem 29 : 2524 2529.
14. Iqbal N., Akula M.R., Vo D., Matowe W.C., McEwen C.A., Wolowyk M.W., Knaus E.E. (1998) Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates. J Med Chem 41 : 1827 1837.
15. Vo D., Matowe W.C., Ramesh M., Iqbal N., Wolowyk M.W., Howlett S.E. et al. (1995) Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4- pyridinylpyridine-5-carboxylate racemates and enantiomers. J Med Chem 38 : 2851 2859.
16. Hemmateenejad B., Miri R., Safarpour M.A., Khoshneviszadeh M., Edraki N. (2005) Conformational analysis of some new derivatives of 4-nitroimidazolyl-1,4- dihydropyridine-based calcium channel blockers. J Mol Struct (Theochem) 717 : 139 152.
17. Miri R., Javidnia K., Sarkarzadeh H., Hemmateenejad B. (2006) Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist. Bioorg Med Chem 14 : 4842 4849.
18. Shafiee R., Rastkary N., Jorjani M., Shafaghi B. (2002) Synthesis and antihypertensive activities of new 1,4-dihydropyridine containing nitroimidazolyl substituent with a nitrooxy group at the 3-ester position. Arch Pharm 2 : 69 76.
19. Shafiee A., Rastkary N., Jorjani M., Shafaghi B. (2002) Synthesis and calcium channel antagonist activity of 1,4-dihydropyridine derivatives containing 4-nitroimidazolyl substituents. Forsch Drug Res 52 : 537 542.
20. Miri R., Niknahad H., Vazin A., Azarpira A., Shafiee A. (2002) Synthesis and smooth muscle calcium channel antagonist effects of new derivatives of 1,4- dihydropyridine containing nitroimidzolyl substituent. DARU 10 : 130 136.
21. Dagnino L., Li-Kwong-Ken M.C., Wynn H., Wolowyk M.W., Triggle C.R., Knaus E.E. (1987) Synthesis and calcium channel antagonist activity of dialkyl 4-(dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates. J Med Chem 30 : 640 646.
22. Ramesh M., Matowe W.C., Knaus E.E., Wolowyk M.W. (1992) Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-[3-(1- methoxy-carbonyl-4-substituted-1,4- dihydro-pyridyl)]-3,5- pyridinedicarboxylates. Drug Des Discov 8 : 313 323.
23. Ramesh M., Matowe W.C., Wolowyk M.W., Knaus E.E. (1999) Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-[4-(1- methoxycarbonyl-1,4-dihydropyridyl)]-3,5-pyridinedicarboxylates. Arch Pharm (Weinheim) 332 : 385 388.
24. Miri R., Javidnia K., Kebriaie-Zadeh A., Niknahad H., Shaygani N., Semnanian S. et al. (2003) Synthesis and evaluation of pharmacological activities of 3, 5-dialkyl 1, 4-dihydro-2,6-dimethyl-4-nitroimidazole-3, 5-pyridine dicarboxylates. Arch Pharm (Weinheim) 336 : 422 428. 25.
25. Iwanami M., Shibanuma T., Fujimoto M., Kawai R., Tamazawa K., Takenaka T. et al. (1979) Synthesis of new water-soluble dihydropyridine vasodilators. Chem Pharm Bull (Tokyo) 27 : 1426 1440.
26. Hansch C., Kurup A., Garg R., Gao H. (2001) Chem-bioinformatics and QSAR: a review of QSAR lacking positive hydrophobic terms. Chem Rev 101 : 619 672.
27. Hemmateenejad B., Miri R., Jafarpour M., Tabarzad M., Foroumadi A. (2006) Multiple linear regression and principal component analysis-based prediction of the anti-tuberculosis activity of some 2-aryi-1,3,4-thiadiazole derivatives. QSAR Comb Sci 25 : 56 66.
28. Hemmateenejad B., Miri R., Tabarzad M., Jafarpour M., Zand F. (2004) Molecular modeling and QSAR analysis of the anticonvulsant activity of some N-phenyl-N'-(4-pyridinyl)-urea derivatives. J Mol Struct Theochem 684 : 43 49.
29. Hemmateenejad B., Miri R., Safarpour M.A., Mehdipour A.R. (2006) Accurate prediction of the blood-brain partitioning of a large set of solutes using ab initio calculations and genetic neural network modeling. J Comput Chem 27 : 1125 1135.
30. Miri R., Niknahad H., Vesal G., Shafiee A. (2002) Synthesis and calcium channel antagonist activities of 3-nitrooxyalkyl, 5-alkyl 1,4-dihydro-2,6- dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3, 5-pyridinedicarboxylates. Farmaco 57 : 123 128.